InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell’s latest podcast features Kelsey Ramsden, Co-Founder and CEO of Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF). During the briefing, Ramsden discussed the company’s business model and the evolving regulatory and social environments surrounding psychedelic-assisted therapy.
“We’re a life sciences company that has two primary focal points. One side is digital therapeutics focused on psychedelic therapy and the other is drug development, again focused on psychedelic molecules,” Ramsden said. “When we developed our model and our strategy of go-to-market … what we looked at was regulation and the timing of regulatory change to ensure that we were developing horizons of revenue that were going to line up with changes at the government level unlocking some of these molecules. What that meant for us was investigating molecular research that would be the blue-sky horizon, so, independent of when the typical generic MDMA or Psilocybin get approved, we’re in charge of the approval process, meaning we do the clinical research on the novel molecule to get it to market. That is drug development. So, that’s one side.”
“The side that was earliest was our digital therapeutics platform. In simple terms, what that means is that the market is going to have a lot of newly trained therapists and a lot of individuals who are new to psychedelic practice,” she continued. “So, we’re developing a clinical-grade, evidence-backed, science-based, AI-driven tool for therapists to deploy psychedelics in their clinics and patients to have an app and a wingman to go through their care, which results in better outcomes, shorter patient timeframes in clinic and, ultimately, approval and unlocking insurance payments for psychedelics.”
To hear the entire podcast and subscribe for future episodes, visit: https://podcast.bell2bell.com.
Ramsden then examined public opinion surrounding psychedelics and their potential benefits as a therapeutic solution.
“We can attach this old stigma around when people hear LSD and they think about college, or we can look at how we’re backing this with research,” she added. “When we see the people that we’re trying to help – people who are suicidal, people who are suffering from addiction – and we look at the options available for them, I think the time has come where we can rely on science and get away from stigma. … As long as we’re getting the data and the clinical research in a highly regulated and structured way, that’ll move the science and the regulation. … I do think we do have some of these hurdles to overcome, but, at the same time, with tools like digital therapeutics and research-backed psychedelics, I think we overcome some of that stigma with science.”
Join InvestorBrandNetwork’s Stuart Smith and Kelsey Ramsden, Co-Founder and CEO of Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF), to learn more about the company’s management team, recent milestones and goals for the remainder of 2021 and beyond.
To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com.
The latest installment of The Bell2Bell Podcast continues to reinforce InvestorBrandNetwork’s commitment to the expansion of its robust network of brands, client partners, followers and the growing IBN Podcast Series. For more than 15 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine
About Mind Cure Health Inc.
Mind Cure Health Inc. is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. For more information, visit the company’s website at www.MindCure.com.
The InvestorBrandNetwork (“IBN”) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through NetworkNewsWire (“NNW”) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.
For more information on IBN, visit https://www.InvestorBrandNetwork.com.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.